TrialThe Lancet. Respiratory medicine2021

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.

Vincent C Marconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.